Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Bradsher Neal C, holds the title of Director at Lineage Cell Therapeutics, Inc..
On 2026-11-17, the insider transacted 1,000,000 shares.The shares were transacted at a weighted average price of $0.77 per share, resulting in a total market-relevant value of $771K.
Bradsher Neal C (Director) bought $771K of $LCTX
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.